Johnson & Johnson is beginning a huge final study to try to prove if a single-dose COVID-19 vaccine can protect against the virus. The study starting Wednesday will be one of the world's largest coronavirus vaccine studies so far, testing the shot in 60,000 volunteers in the U.S., South Africa, Argentina, Brazil, Chile, Colombia, Mexico and Peru. A handful of other vaccines in the U.S. — including shots made by Moderna Inc. and Pfizer Inc. — and others in other countries are already in final-stage testing.
The maker of anti-influenza drug Avigan said Wednesday it will apply for the medication to be approved for treating coronavirus patients after trials showed it can shorten recovery time.
Novartis's bid to expand its $2.1 million-per-patient gene therapy Zolgensma to more spinal muscular atrophy patients faces a possible delay after U.S. regulators requested another study in older children getting the drug via a spinal infusion. Novartis, whose shares fell 1% in early Wednesday trading, said the U.S. Food and Drug Administration's (FDA) request for an additional study was not linked to an ongoing safety hold on a Zolgensma trial after possible neurological damage in primates emerged last year. The Basel-based company also said the move to satisfy the FDA would not affect the therapy's existing approval in babies up to two years with the rare genetic condition.
Authorities in Spain's Madrid region on Wednesday requested urgent help to hire hundreds of foreign doctors and reinforce police, as they mulled widening a partial coronavirus lockdown to more areas as cases rise. The region is the hardest-hit in Spain by a second wave of the coronavirus and has restricted movement between and within some districts that are home to about 850,000 people. Ignacio Aguado, the deputy head of the regional government, told reporters the region needed 300 doctors from outside the European Union who had worked in the first wave of the pandemic, but could not hire them immediately due to complex regulations.
“Enfranchising 16-year-olds would be good for them and good for our democracy.”
“At 16, most kids have little awareness of politics, civics, or American history.”
“Voting is habit forming...which underscores the importance of having as stable an environment as possible for the youngest voters.”
“Keeping the voting age at 18 is not a slap at 16-year-olds. It is recognition that an informed electorate is the best kind.”
“When young people’s participation lags badly, issues important to them receive short shrift in the public discourse.”